Abstract
Cancer patients often exhibit immunosuppression that is caused by the expanding tumor mass. This fact has severely compromised many efforts to develop effective cancer vaccines in the past. However, a new generation of immunotherapies takes focus on both activating the effector cells of the immune system as well as reverting the immunosuppression. This two-step process has lead to impressive anti-tumor effects both in experimental settings as well as in initial clinical trials. With new and powerful techniques for genetic engineering, the transfer of immunostimulating genes has gained interest. Genetic engineering of the tumor micromilieu has, for example, shown to be an effective means for breaking tumor-induced immunosuppression in an experimental model of bladder cancer. Genetic engineering can also be used to modify the immune effector cells to efficiently target tumor cells and to simultaneously resist immune inhibition. This review will discuss the immunological status of cancer patients with focus on T regulatory cells and their inhibitory cytokines as well as offer a survey of novel immune strategies for cancer gene therapy.
Keywords: Gene therapy, cancer vaccine, genetic engineering, immunotherapy, DC vaccine, T regulatory cells
Current Cancer Therapy Reviews
Title: Genetic Engineering - A New Era for Cancer Immunotherapy?
Volume: 3 Issue: 3
Author(s): Angelica Loskog and Thomas H. Totterman
Affiliation:
Keywords: Gene therapy, cancer vaccine, genetic engineering, immunotherapy, DC vaccine, T regulatory cells
Abstract: Cancer patients often exhibit immunosuppression that is caused by the expanding tumor mass. This fact has severely compromised many efforts to develop effective cancer vaccines in the past. However, a new generation of immunotherapies takes focus on both activating the effector cells of the immune system as well as reverting the immunosuppression. This two-step process has lead to impressive anti-tumor effects both in experimental settings as well as in initial clinical trials. With new and powerful techniques for genetic engineering, the transfer of immunostimulating genes has gained interest. Genetic engineering of the tumor micromilieu has, for example, shown to be an effective means for breaking tumor-induced immunosuppression in an experimental model of bladder cancer. Genetic engineering can also be used to modify the immune effector cells to efficiently target tumor cells and to simultaneously resist immune inhibition. This review will discuss the immunological status of cancer patients with focus on T regulatory cells and their inhibitory cytokines as well as offer a survey of novel immune strategies for cancer gene therapy.
Export Options
About this article
Cite this article as:
Angelica Loskog and Thomas H. Totterman , Genetic Engineering - A New Era for Cancer Immunotherapy?, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368341
DOI https://dx.doi.org/10.2174/157339407781368341 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity
Current Medicinal Chemistry Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control
Current Drug Safety Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
Current Pharmaceutical Design Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry Tachykinins and the Cardiovascular System
Current Drug Targets Fanconi Anemia Proteins, DNA Interstrand Crosslink Repair Pathways, and Cancer Therapy
Current Cancer Drug Targets Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine Medicinal Treatments of Cholesterol Gallstones: Old, Current and New Perspectives
Current Medicinal Chemistry Molecular Imaging in Optical Coherence Tomography
Current Molecular Imaging (Discontinued) Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Nanomedicines for Intravesical Chemotherapy in Bladder Cancer
Current Pharmaceutical Design Cyclophilin function in Cancer; lessons from virus replication
Current Molecular Pharmacology The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine The Advancement of Human Serum Albumin-Based Molecular Probes for Molecular Imaging
Current Pharmaceutical Design